drugset / Trial / NCT00582894
Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases
NaSingle-groupOpen-labelTreatment
Summary
To evaluate engraftment and toxicity of a reduced intensity preparative regimen for patients who receive a matched related or unrelated donor allogeneic stem cell transplant (ASCT) for malignant hematological diseases
Timeline
- Start
- 2005-02
- Primary completion
- 2008-03
- Completion
- 2008-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alemtuzumab | Monoclonal antibody | 10 mg | Intravenous |
| Subject | Busulfan | Small molecule | 3.2 mg/kg | — |
| Subject | Fludarabine | Small molecule | 30 mg/m2 | — |